Sino Biopharmaceutical Ltd 2023 SR
The report details Sino Biopharmaceutical Limited's ESG performance for 2023, guided by its CARE strategy. The company achieved a 13% reduction in greenhouse gas emission intensity compared to 2021 and increased renewable energy consumption by 76.64%. Significant progress was made in healthcare accessibility, with 27 new products approved for marketing and over 150 million patients covered by key products. The Group invested RMB 4.4 billion in R&D and RMB 56.78 million in public welfare initiatives. Furthermore, its MSCI ESG rating was upgraded to A, reflecting its commitment to sustainable development and corporate responsibility.
Company: Sino Biopharmaceutical Ltd
Sector: Manufacturing
Country: Hong Kong
Year: 2023
Type: SR
Pages: 79
Back to company
Sino Biopharmaceutical Ltd
ESG Report
The report details Sino Biopharmaceutical Limited's ESG performance for 2023, guided by its CARE strategy. The company achieved a 13% reduction in greenhouse gas emission intensity compared to 2021 and increased renewable energy consumption by 76.64%. Significant progress was made in healthcare accessibility, with 27 new products approved for marketing and over 150 million patients covered by key products. The Group invested RMB 4.4 billion in R&D and RMB 56.78 million in public welfare initiatives. Furthermore, its MSCI ESG rating was upgraded to A, reflecting its commitment to sustainable development and corporate responsibility.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Apr 25, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees